Glucolipotoxicity (GLT), in which elevated levels of glucose and fatty acids have deleterious
effects on β-cell biology, is thought to be one of the major contributors in progression of type …

Type 2 diabetes is marked by progressive β-cell failure, leading to loss of β-cell mass.
Increased levels of circulating glucose and free fatty acids associated with obesity lead to β …

Type 2 diabetes (T2D) is caused by loss of pancreatic β-cell mass and failure of the
remaining β-cells to deliver sufficient insulin to meet demand. β-Cell glucolipotoxicity (GLT) …

Aims/hypothesis A leading cause of type 2 diabetes is a reduction in functional beta cell
mass partly due to increased beta cell death, triggered by stressors such as glucolipotoxicity …

Aims/hypothesis We have provided evidence that glucagon-like peptide-1, a potential
therapeutic agent in the treatment of diabetes, activates phosphatidylinositol-3 …

Progressive loss of pancreatic β-cell functional mass and anti-diabetic drug responsivity are
classic findings in diabetes, frequently attributed to compensatory insulin hypersecretion and …

Glucagon-like peptide–1 (GLP-1) and angiotensin II type 1 receptor blocker reduce β-cell
apoptosis in diabetes, but the underlying mechanisms are not fully understood. We …

Loss of beta cells is a pathogenic cause for the development of type 2 diabetes. High
glucose/free fatty acid (HG/FFA)-induced glucolipotoxicity was thought to play a role in the …

Background Chronic hyperglycemia has deleterious effects on pancreatic β-cell function and
turnover. Recent studies support the view that cyclin-dependent kinase 5 (CDK5) plays a …

The recent epidemic of type 2 diabetes in Asia differs from that reported in other regions of
the world in several key areas: it has evolved over a much shorter time, in an earlier stage of …